Article Details

Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide

Retrieved on: 2024-02-04 22:18:29

Tags for this article:

Click the tags to see associated articles and topics

Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide. View article details on hiswai:

Excerpt

Meredith Cummings on Using Machine Learning to Predict Treatment-Related Adverse Events · Alyssa Ridad. Ridad and McKaig Discuss Oncology Nurse ...

Article found on: www.oncnursingnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo